Eli Lilly just dropped their Q3 2025 earnings, and it’s clear the GLP-1 era has entered a new phase. Lilly now controls 6 out of 10 GLP-1 prescriptions in the U.S., driven by massive demand for Zepbound, Mounjaro, and soon Orforglipron, the first oral GLP-1 pill for obesity that could hit the market as early as 2026. In this episode of On The Pen, we break down the key takeaways from Lilly’s call: • Zepbound’s meteoric growth and how 40% of new prescriptions now flow through Lilly Direct • Orforglipron’s global submissions for obesity and type 2 diabetes with a possible priority FDA review that could mean approval in as little as 1 to 2 months • Retatrutide’s next trials for obesity and osteoarthritis pain • What Dave Ricks really meant when he said a $100 GLP-1 pill would “stifle innovation” • The growing tension between innovation and affordability in obesity medicine This isn’t just a numbers story. It’s about access, cost, and the fight for who gets to afford staying healthy.